ArcticZymes Technologies — Investor Presentation 2018

Nov 13, 2018

High margin growth business

November 13, 2018 Christian Jørgensen, CEO

Disclaimer

This presentation contains certain forward-looking information and statements. Such forward-looking information and statements are based on the current, estimates and projections of the Company or assumptions based on information currently available to the Company. Such forward-looking information and statements reflect current views with respect to future events and are subject to risks, uncertainties and assumptions. The Company cannot give assurance to the correctness of such information and statements. These forward-looking information and statements can generally be identified by the fact that they do not relate only to historical or current facts.

Forward-looking statements sometimes use terminology such as "targets", "believes", "expects", "aims", "assumes", "intends", "plans", "seeks", "will", "may", "anticipates", "would", "could", "continues", "estimate", "milestone or other words of similar meaning and similar expressions or the negatives thereof. By their nature, forward-looking information and statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements that may be expressed or implied by the forward-looking information and statements in this presentation. Should one or more of these risks or uncertainties materialize, or should any underlying assumptions prove to be incorrect, the Company's actual financial condition or results of operations could differ materially from that or those described herein as anticipated, believed, estimated or expected.

Any forward-looking information or statements in this presentation speak only as at the date of this presentation. Except as required by the Oslo Stock Exchange rules or applicable law, the Company does not intend, and expressly disclaims any obligation or undertaking, to publicly update, correct or revise any of the information included in this presentation, including forward-looking information and statements, whether to reflect changes in the Company's expectations with regard thereto or as a result of new information, future events, changes in conditions or circumstances or otherwise on which any statement in this presentation is based.

Given the aforementioned uncertainties, prospective investors are cautioned not to place undue reliance on any of these forward-looking statements.

Biotec listed on OSE- investment opportunity

A corporation with two technology platforms originating from Tromsoe University who both benefit from underlying market growth

Beta-glucans

• A unique platform for products with immune modulating effects
• Woulgan proven to reactivate wound healing and with commercial progress in key markets
• An adjuvant in selected cancer treatments

Enzymes

Novel enzyme technologies focusing on:

• Molecular biology
• Molecular diagnostics
• Biomanufacturing

Beta-glucans

A unique platform for products with immune modulating effects

Woulgan® opportunity

• Stalled wounds are a growing global problem 1-2% of population experience chronic wound during lifetime.

• 60% chronic wounds become stalled (5%+ of DFU's result in amputation).

• Reimbursed in the Nordics, UK and Germany.
• UK study (300 pts) showing 60% healing with Woulgan versus 30% w. standard care in chronic wounds.
• Investigating partner opportunities to drive sales

SBG® in Neuroblastoma vaccine trial

SBG® and Neuroblastoma

• High impact indication in children (<50% survival in high-risk patients)
• Proof of concept study for use of SBG® as adjuvant in immunotherapy of cancer

Patients under treatment

Data from trial presented at Advances in Neuroblastoma Research 2018 at 9-12 May in San Francisco

• 84 patients with relapsed neuroblastoma treated with vaccine + SBG
• Two years overall survival 90% and progression free survival of 54% in this high-risk patient group
• Improved outcome correlate with immune response to vaccine
• SBG seem to induce improved immune response and higher antibody titer towards the vaccine.

6 Relapse-free survival (red) and overall survival (black) of the 15 study patients from the start of the vaccination (Kushner et al 2014, Clinical Cancer Research 20:1375-1382).

SBG® in immunotherapy of neuroblastoma

Clinical trial program of the bivalent ganglioside vaccine in combination with SBG® for high-risk neuroblastoma

2009 – 2013 Phase I Safety	2013 – 2016 Phase I/ II Efficacy	2016 – 2019 Phase II Efficacy	2019 – 2021 Phase II/III Efficacy
≥2nd remission patients	≥2nd remission patients	≥1st remission patients	Multi-site Randomised Controlled Trial ≥1st remission patients
15 patients. Results published in Clinical Cancer Res 2014	84 patients. Initial results presented at ANR18 in San Francisco May 2018.	161 additional patients to be included (260 in total).	Under planning
Safety in relapsed patient population	Efficacy in relapsed patient population.	Commence initial approval process	Possible approval of combined treatment for relapsed neuroblastoma

ArcticZymes

Novel enzyme technologies focusing on:

molecular biology, molecular diagnostics and biomanufacturing

Molecular Enzyme Market \$1.5 Bil

Launched 5 new products in 10 months

ArcticZymes Road Map

• Combination of investment in organic and non-organic growth initiatives
• Commercialize a relevant and broader synergistic OEM product portfolio

• Leverage increased capacity and higher-level sales expertise with new business development team

• 2 technology platforms generating high value products in growth segments

• Beta-glucans:
• As a possible adjuvant together with a vaccine against relapse of Neuroblastoma.
• In a well documented wound care product with significant improved outcome addressing a large issue.

• Enzymes:

• Creating unique enzymes used in high value environments like molecular diagnotics, molecular biologics and biomanufacturing.

Contact: Børge Sørwoll, CFO bso@biotec.no Tel: +47 9529 0187 www.biotec.no

Thank you!